



Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR)


RECORD: 2021-044 PEPTIDES SYNTHESIS SERVICES (IC120/00076)

**DOCUMENT OF TECHNICAL SPECIFICATIONS
NOT HARMONIZED TRADE – OPEN PROCEDURE**

**SYNTHETIC PEPTIDES SYNTHESIS SERVICES FOR THE EXPERIMENTAL
THERAPEUTICS RESEARCH GROUP OF THE FUNDACIÓ HOSPITAL UNIVERSITARI
VALL HEBRON – INSTITUT DE RECERCA (VHIR).**

Funded by the "Fondo Europeo de Desarrollo Regional" (FEDER).





Clause 1. Aim of the tender.

The purpose of this contract is to provide the synthetic peptides synthesis services for the Experimental Therapeutics Research Group of the Fundació Hospital Universitari Vall Hebron – Institut de Recerca (VHIR) in charge of project (ICI20/00076) entitled “*Next generation TIL therapy targeting neoantigens for immune checkpoint blockade-resistant tumors*”; according to what is stipulated in the Document of Technical Specification, financed by the Instituto de Salud Carlos III (Ministerio de Ciencia, Innovación y Universidades).

Throughout these specifications, the tasks included in the object of this contract are specifically described, as well as the scope of the proposed service.

Clause 2. Maximum budget of the tender.

The estimated value and maximum budget for this tender are the same.

The total maximum budget for this tender annually, as well as the estimated value for this tender is “**FIFTY THOUSAND EIGHT HUNDRED SIXTY-EIGHT EUROS WITH SEVENTY-FIVE CENTS**” (€ 50,868.75), VAT not included to which, if we add the amount of “**TEN THOUSAND SIX HUNDRED EIGHTY-TWO EUROS WITH FOURTY FOUR CENTS**” (€ 10,682.44) corresponding to VAT, we add a total of “**SIXTY-ONE THOUSAND FIVE HUNDRED FIFTY-ONE EUROS WITH NINETEEN CENTS**” (€61,551.19).

As detailed below, the provision of services will consist of the synthesis of peptides from 25 aa or 8-12 aa with different levels of purity and its subsequent shipment. These peptides will be used to screen for neoantigen-specific lymphocytes.

Therefore, the maximum total budget for each service unit to be performed will be:

- **Synthesis of peptides on a small scale of “crude” purity (25 aa):** € 15 (VAT excluded)
 - **Approximate units:** 2250 peptides
 - **Maximum price for 2250 different peptides:** € 33,750.00 (VAT excluded)
-
- **Synthesis of peptides on a small scale of “crude” purity (8-12 aa):** € 19 (VAT excluded)
 - **Approximate units:** 300 peptides
 - **Maximum price for 300 different peptides:** € 5,700.00 (VAT excluded)



- **Customized peptide synthesis with purity >70% HPLC (8-12 aa): € 72.50 (VAT excluded)**
 - **Approximate units:** 45 peptides
 - **Maximum price for 45 different peptides: €3,262.50 (VAT excluded)**

- **Customized peptide synthesis with purity >70% HPLC (25 aa): € 181.25 (VAT excluded)**
 - **Approximate units:** 45 peptides
 - **Maximum price for 45 different peptides: € 8,156.25 (VAT excluded)**

(*) Price that the tenderer, will be able to improve in the ECONOMIC OFFER – envelope C.

In no case will the estimate of the volume in the provision of the service be binding, the VHIR will pay the invoices for the service actually provided, detailing the duly signed delivery note numbers on the invoice.

Concept	Price (VAT not included)
Maximum budget	50.868,75 Euros
Possible modifications	00,00 Euros
Possible extensions	00,00 Euros
Total	50.868,75 Euros

*** The service must comply with all legal requirements at the time of contracting, and throughout the term of the contract.

Clause 3. Duration of the contract.

The duration of this service contract will coincide with the duration of the aforementioned project, which is until December 31, 2023, the end date of the Project (IC120 / 00076).

However, if this project is found, for any of the reasons that cannot now be foreseen, subject to the request for a possible extension, the completion date will be subject to be extended, at most the one that is finally authorized.



Clause 4. Description of the service and scope of the object of the contract.

The service that is the object of this tender consists of the synthesis of synthetic peptides of different sizes and purities to be able to screen the TILs against neoantigens.

The budget includes the following conditions:

- Synthesis of 10-50 ug of 25aa “crude” peptides, capping after each step. N-terminal amino and C-terminal aa or glycine. Includes 5% LC-MS analysis.
- Synthesis of 10-50 ug of 25aa “crude” peptides, capping after each step. N-terminal amino and C-terminal aa single. Includes analysis of each peptide by LC-MS of all peptides.
- Synthesis of 1 mg of peptides with > 70% purity (HPLC) of 25aa. N-terminal amino and C-terminal aa single. Includes HPLC and MS purity analysis.
- Synthesis of 1 mg of peptides with > 70% purity (HPLC) of 8-12 aa. N-terminal amino and C-terminal aa single. All peptides are purified and retested by LC-MS.
- Peptides will be produced without animal derived compounds.
- Peptides will be shipped in freeze-dried format.

Clause 5. Other service requirements.

- No type of subcontracting will be admitted in the global sequencing process.
- **The Company must present in ENVELOPE 1 the certificate of accreditation of compliance with the ISO 9001: 2015 standard.** Companies that do not accredit it will be excluded.

Clause 6. Billing and payment.

The contractor will invoice the service through its corresponding invoice, which must be sent to the following email address: factures@vhir.org.

Each invoice issued must detail the period to which it corresponds, the breakdown / description of expenses by concept, as well as indicate the references “**LICI-2021-044 PEPTIDES SYNTHESIS SERVICES (ICI20/00076)**”.



The effective payment of the executed services will be made by bank transfer, with a maturity of 30 days / invoice date.

The contracting entity pays for the services once they have been carried out in part or in full and once the invoice has been entered in its register. According to this parameter, the advance payment of part or all of the contract price is not contemplated.

Under no circumstances will the contractor be entitled to a price review for any reason.

Clause 7. Responsible for the contract.

The person in charge of the contract is the Principal Investigator of the Therapeutics Experimental Research Group of the Fundació Hospital Universitari Vall Hebron - Institut de Recerca, who will be basically responsible, among others, for the functions of management and supervision of the contracted supply, conforming the invoicing issued by the service; monitoring, control and dictation of the instructions necessary for the proper execution of the contract; determine whether the service provided complies with the requirements established for its execution and compliance and receipt of the contract at the end, and comply with the obligations assumed by the Vall Hebron University Hospital Foundation - Research Institute (VHIR) in this contract.

Clause 8. Location and Schedule of service provision.

Location:

The successful bidder will provide the service that is the object of this tender under the ICI20 / 00076 Project of Dra. Elena Garralda Cabanas, from the Experimental Therapeutics Research Group located in the Cellex Building, c / Natzaret 115.

Clause 9. Confidentiality, Protection of personal data, and Intellectual Property

Notwithstanding the provisions of current legislation on intellectual property, protection of personal data and confidentiality, the successful bidder will expressly commit itself not to provide the information and / or Data provided by the VHIR, or any use not provided for in this document, and / or expressly authorized by the Head of the assigned Unit.

The successful bidder will have to extend to the employees that adhere to the service, the obligations contained and assumed by the successful bidder, with reference to confidentiality, intellectual property and protection of Data, in particular those relating to the



secret, the reservation and confidentiality of all the information that, under the service, may be aware of.

These will be understood as being exclusively granted in favor of the VHIR worldwide, for the maximum time established in applicable laws and / or international treaties that are applicable and for their exploitation through any format and / or modality of exploitation, all rights, including the exploitation of any discovery, invention, creation, work, procedure, idea, technique, drawing, design, image or any other intellectual or industrial property right generated, raised or acquired as a consequence of the work carried out by the company awarded the contract that is derived from this tender procedure (hereinafter, "Intellectual and / or Industrial Property"), and which derive directly or indirectly from the relationship between VHIR and I The company awarded by the contract that is derived from this tender procedure.

The company that awards the contract that is derived from this tender procedure undertakes to inform the VHIR of any discovery, creation, invention, idea or any other element that constitutes or is likely to constitute a right of Industrial Property and / or Intel Legal and that develops partially or totally during the term of the contract that is derived from this tender procedure. In the event that the contracting company that derives from this tender procedure discovers or develops any creation of intellectual or industrial property, it will be understood that the discovery or development constitutes confidential information of the VHIR.

The company that awards the contract that is derived from this tender procedure undertakes to sign all those public and / or private documents that are necessary, at the discretion of the VHIR, to allow the accreditation of the ownership of the VHIR or the proper protection of the aforementioned rights of Intellectual Property and / or Industrial in favor of the same or of any third party designated by it.

The company that awards the contract that is derived from this tender procedure authorizes the VHIR for the transformation, modification, publication, public communication and exploitation by any means of the works that it develops as a result of the execution of the contract that is derived from it This tender procedure.

Clause 10. Allocation criteria.

Each bidder must provide a technical as well as a financial offer. Contracts will be awarded according to criteria based on an approach that takes into account the best cost-effectiveness ratio, a circumstance that will be evaluated according to the following criteria:

For the evaluation of the tender proposals and the determination of the most economically advantageous, the following criteria and weighting percentages will be used:



1. Economic offer: MAXIMUM 50 POINTS.

This criterion for award (economic offer) will be assessed automatically according to the formula below:

$$P(N) = M \times (2 - N/B)$$

P(N): Score of bid N
M: Maximum possible score
B: Best bid submitted
N: Bid to be assessed

* If after applying the automatic formula to a submitted offer, the resulting value is negative, zero (0) points will be directly assigned to the economic part. **P (N) = 0.**

The following criteria will be evaluated through **value judgments**. The award criteria for assessing the contents of envelope No. 2 are as follows:

2. Supply technical characteristics MAXIMUM 50 POINTS.

2.1 Work plan and organization (up to 25 points).

Tenderers must submit an organizational and service development proposal. This work plan must include: objectives, phases, planned dedication and schedule of actions to be carried out.

2.2 Writing a report on the provision of the service (up to 25 points).

Report on the provision of the service that includes:

- Control and monitoring plan, which includes a system of indicators for the evaluation of partial results (monitoring of visits, writing of reports that summarize the steps and contacts made, pre-agreements, future prospects ...).
- Action protocols during the provision of the service in the face of different situations that may arise during the development of the planned tasks.

Barcelona, 05 of July 2021.

CONTRACTING ORGANISM

Dr. Joan X. Comella Carnicé

Director

Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR).